Latest / Pharmacy Podcast Network / Lipid Disturbances in Alzheimer's | Geriatric Pharmacy Focus
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:27Speaker 1: We have an aging population taking more medications than ever before.
- 0:31Speaker 1: On this podcast, I will interview experts in geriatric medicine
- 0:34Speaker 1: to gain insights so we can provide optimal care to
- 0:37Speaker 1: patients in their golden ears. I'm your host, doctor Tammer Ruggles,
- 0:40Speaker 1: and this is the Geriatric Pharmacy Focus. Welcome to the
- 0:49Speaker 1: Geriatric Pharmacy Focus. I am your host, Doctor Tamar Ruggles.
- 0:52Speaker 1: I have a fascinating episode for you today on cholesterol
- 0:55Speaker 1: disturbances in the brain of those with Alzheimer's disease.
- 0:59Speaker 2: So a few weeks ago, I posted on.
- 1:00Speaker 1: LinkedIn about my dad who is seventy six and has
- 1:03Speaker 1: been healthy, never really taken a prescription medication other than
- 1:07Speaker 1: for the occasional infection his entire life, and has had
- 1:10Speaker 1: a normal lipid panel his entire life, yet had a
- 1:13Speaker 1: coronary artery calcium score greater than five hundred. So after
- 1:17Speaker 1: that post, my guest today Josh reached out and shared
- 1:20Speaker 1: a few excerpts up from his books.
- 1:22Speaker 2: He has two of.
- 1:22Speaker 1: Them, The home Security System in the lipid neighborhood. He's
- 1:26Speaker 1: got a really interesting background as a physical therapist, an
- 1:28Speaker 1: IVY League grad, a collegiate track athlete, and also done
- 1:33Speaker 1: some PhD work in lipid disturbances in Alzheimer's. So, with
- 1:37Speaker 1: nearly seven million Americans living with Alzheimer's and that number
- 1:40Speaker 1: projected to grow to nearly thirteen million by twenty fifty,
- 1:44Speaker 1: I'm excited to visit with Josh day about Alzheimer's and
- 1:46Speaker 1: how lipid disturbances may be contributing. So welcome Josh to
- 1:50Speaker 1: the podcast. And if you could just start by telling
- 1:52Speaker 1: us a bit about your background and how you became
- 1:55Speaker 1: interested in lipid's and Alzheimer's.
- 1:59Speaker 3: Yeah, thank you so much for having me. Anytime you
- 2:02Speaker 3: can get doctor day Spring on the podcast. That's a riot.
- 2:06Speaker 3: Any of us in the lipid space have learned so
- 2:08Speaker 3: much from him over the years, and I think he's
- 2:10Speaker 3: helped to ignite my fire and my passion for learning
- 2:14Speaker 3: all these biochemical pathways, but more importantly shifting our paradigm
- 2:18Speaker 3: from reactionary to prevention. And so anyway, so my background
- 2:24Speaker 3: is unique, I think, and so if there's anybody else
- 2:27Speaker 3: with an identical background, I would love to meet that person.
- 2:31Speaker 3: Because my first doctor it was actually in physical therapy,
- 2:35Speaker 3: so I am a physical therapist as well among many
- 2:38Speaker 3: other titles, but that was.
- 2:40Speaker 2: My first doctorate.
- 2:41Speaker 3: And you know, I firmly believe that God uses various events,
- 2:46Speaker 3: even hard events, to catalyze what we're really supposed to
- 2:48Speaker 3: do when we grow up. And I got really, really
- 2:50Speaker 3: sick actually when I was in grad school the first time,
- 2:54Speaker 3: and a myriad of antocrinological disturbances, and it actually made
- 3:00Speaker 3: felt fall in love with endochronology and biochemistry and all
- 3:03Speaker 3: these things because I was like, Wow, this stuff is
- 3:05Speaker 3: really interesting. And so anyway, long story short, I finished
- 3:09Speaker 3: PT school practice as a physical therapist for years. Very grateful,
- 3:14Speaker 3: very blessed to be involved in people's lives in the
- 3:16Speaker 3: rehabit realm. But there's never any sense of finality that
- 3:20Speaker 3: I was done with school because I kind of like school.
- 3:23Speaker 2: It's an expensive habit.
- 3:24Speaker 3: So that's that's my one of my wife is she's
- 3:28Speaker 3: encouraged me to, you know, pick up some other hobbies.
- 3:30Speaker 2: So that's why I wrote a book.
- 3:31Speaker 3: And actually my book that you mentioned, the home security
- 3:34Speaker 3: system in the Lipid neighborhood that releases February eighteenth, and
- 3:37Speaker 3: so you know put that on your you know, on
- 3:40Speaker 3: your calendar there, so it should be a should be
- 3:42Speaker 3: a fun time. But anyway, so I actually went back
- 3:45Speaker 3: to PA school because I figured I was like, okay, well,
- 3:48Speaker 3: I think the quickest means to my end to try
- 3:51Speaker 3: to save the world from all sorts of metabolic arrangements
- 3:54Speaker 3: is going to go to PA school. And so I
- 3:56Speaker 3: went through the Yale School of Medicine. It was fantastic,
- 3:59Speaker 3: had a wonderful time there, and then I actually ended
- 4:02Speaker 3: up practicing in indo chronology and at a metabolic clinic
- 4:06Speaker 3: for several years. And yeah, my passion for lipids was
- 4:11Speaker 3: ignited in a kind of strange way. I wish I
- 4:14Speaker 3: had a really good, like humanitarian reason for getting into lipids,
- 4:20Speaker 3: but in reality, I was sitting there on a cold
- 4:23Speaker 3: January day and I had a patient cancel, and I'm
- 4:26Speaker 3: always reading stuff, and I pulled up this article and
- 4:30Speaker 3: it had this just obnoxiously condescending title, something like Basics
- 4:34Speaker 3: of Life of Proteins.
- 4:35Speaker 2: And I'm like, okay, come on, you know I'm pretty
- 4:38Speaker 2: good at biochemistry. How hard can this stuff be?
- 4:41Speaker 3: And so I read this article that was supposed to
- 4:43Speaker 3: be rudimentary, and I really didn't understand hardly any of it,
- 4:47Speaker 3: and it made me mad.
- 4:48Speaker 2: And so anyway, so I was like, well, that's unacceptable
- 4:52Speaker 2: given that this is incredibly important and incredibly relevant to
- 4:55Speaker 2: athroscorosis and coronary disease, which is, you know, the number
- 4:59Speaker 2: one killer pe across the world. So I was like, well,
- 5:01Speaker 2: this is probably worth learning, and.
- 5:03Speaker 3: So I devoted myself to learn and all this stuff
- 5:07Speaker 3: and and that's really what you know, created this monster,
- 5:11Speaker 3: I suppose, And and I became a clinical lipid specialist,
- 5:14Speaker 3: started seeing people and patients for some of these other
- 5:18Speaker 3: you know, lipid lipid disorders, you know, the lysosomal acid
- 5:21Speaker 3: life based deficiency every now and then some familiar kyle
- 5:23Speaker 3: micronemia syndrome, and a lot of people that just had
- 5:27Speaker 3: had events unfortunately, and we were trying to get things
- 5:29Speaker 3: under control to to make sure that they wouldn't have
- 5:32Speaker 3: recurrent events.
- 5:32Speaker 2: And so anyway, so that's that's how it kind of happened.
- 5:36Speaker 3: And then I transitioned to a role in industry a
- 5:38Speaker 3: few years ago as a medical science liaison. And you know,
- 5:42Speaker 3: nothing we're going to talk about today as any irrelevance
- 5:45Speaker 3: to uh to amgin. This is all my own opinions,
- 5:48Speaker 3: my own perspectives, and uh, that's that's my caveat here.
- 5:51Speaker 3: So we can have some unadulterated fun talking about all
- 5:55Speaker 3: the wonderful things.
- 5:57Speaker 2: And and I.
- 5:58Speaker 3: You know, on on the side, I was on a
- 6:00Speaker 3: PhD this whole time in lipid disturbances in Alzheimer's and
- 6:03Speaker 3: finish that up. And there's all sorts of stuff that
- 6:06Speaker 3: we're going to talk about today, and I'm excited to
- 6:09Speaker 3: do so.
- 6:10Speaker 1: Well, that's amazing what a background. Yeah, school is expensive,
- 6:14Speaker 1: but it is so fun to keep learning. I'm often
- 6:17Speaker 1: tempted to go back myself, but my husband so kindly
- 6:20Speaker 1: reminds me that's probably not a good idea at this
- 6:22Speaker 1: point in our lives.
- 6:24Speaker 2: So let's start.
- 6:26Speaker 1: Maybe you could start with just explaining your framework for
- 6:29Speaker 1: lipids and cardiovascular risks below the brain first, and then
- 6:32Speaker 1: maybe we'll get into the lipids in the brain next.
- 6:36Speaker 2: Yeah.
- 6:36Speaker 3: I think that's a wonderful idea, just because having appropriate
- 6:40Speaker 3: context is critical to start to make some sense of
- 6:43Speaker 3: the litany of factors that influence both cardiac health and
- 6:47Speaker 3: brain health. And in a lot of ways, what's good
- 6:50Speaker 3: for the heart is good for the brain. But there
- 6:51Speaker 3: are definitely some some quirks and some idiosyncrasies.
- 6:55Speaker 2: That happen in the central nervous system.
- 6:57Speaker 3: But for me, and this is a lot of what
- 6:59Speaker 3: my books about, is for everybody who doesn't want to
- 7:02Speaker 3: have heart attacks, strokes and dementia. I want you to
- 7:05Speaker 3: have a great home security system, and I want you
- 7:07Speaker 3: to live in a safe lipid neighborhood. Your home security
- 7:10Speaker 3: system has four basic pillars, normal blood sugar, normal blood pressure,
- 7:14Speaker 3: keep inflammation low, and don't smoke.
- 7:15Speaker 2: Or do drugs so bad.
- 7:18Speaker 3: But then your lipid neighborhood is your cholesterol panel because
- 7:21Speaker 3: every APO B particle, the majority of those being LDL
- 7:25Speaker 3: are potentially criminals that can get into your neighborhood. And
- 7:28Speaker 3: then the LP little A particles are the felons because
- 7:31Speaker 3: per particle, they're about six and a half times as
- 7:34Speaker 3: athrogenic as your run of the mill L DEAL particle.
- 7:36Speaker 2: You know, that's a genetic factor.
- 7:37Speaker 3: That has been gaining awareness that everybody should be checked
- 7:40Speaker 3: at least once in a lifetime. So how's your home
- 7:43Speaker 3: security system? We have many ways of measuring that. You know,
- 7:46Speaker 3: how's your blood sugar. How's your blood pressure? You know,
- 7:48Speaker 3: are your inflammatory markers up?
- 7:50Speaker 2: You know? Are you smoking? Probably should stop, you know,
- 7:53Speaker 2: but you know, people don't live on paper with their
- 7:56Speaker 2: lipid panel.
- 7:56Speaker 3: And you mentioned your dad had had a you know,
- 7:58Speaker 3: relatively normal lipid panel, you know, or it was said
- 8:01Speaker 3: to be normal.
- 8:02Speaker 2: Well, got plaque.
- 8:04Speaker 3: Get a CAC, which is the colonoscopy of the heart
- 8:07Speaker 3: without the nasty pregame show.
- 8:08Speaker 2: And I'm really glad that your dad got that.
- 8:11Speaker 3: I'm a huge fan of corner Ardie calcium scores because
- 8:14Speaker 3: it shows, hey, have you been broken into?
- 8:16Speaker 2: Right?
- 8:17Speaker 3: And if you have been broken into, if your physiologic dwelling.
- 8:20Speaker 2: Has been compromised, well, what are we going to do
- 8:23Speaker 2: about it? Do you want to keep living in the
- 8:25Speaker 2: same rough neighborhood where you got broken into? Or do
- 8:28Speaker 2: we have the option of moving you to a nice, safe,
- 8:30Speaker 2: gated community with fewer criminals. And we do, And so
- 8:34Speaker 2: that's really the preventive approach. And yes CAC isn't a perfect.
- 8:38Speaker 3: Score, but it's a great screen, right, And it's it's
- 8:41Speaker 3: similar to me, if to a kolonoscopy, when when you
- 8:43Speaker 3: go and you get a kolonoscopy, I mean it ruins
- 8:45Speaker 3: your social life temporarily.
- 8:46Speaker 2: But you know, if you have a pall up or two,
- 8:49Speaker 2: you know, they don't wait around for you to just
- 8:51Speaker 2: get colon cancer, right, you know, they take them out
- 8:54Speaker 2: and then you check back at you know, regular intervals.
- 8:56Speaker 2: Well with a CAC, you.
- 8:58Speaker 3: Know, if you have an elevated score, well, do we
- 9:00Speaker 3: just wait around for you to have an event? Probably
- 9:03Speaker 3: ought to not do that, and we have ways to
- 9:05Speaker 3: mitigate that risk. And so anyway, so I'm a big
- 9:08Speaker 3: fan of prevention and helping people make sense of the
- 9:12Speaker 3: purpose of cholesterol and the purpose of lipoproteins, because really,
- 9:16Speaker 3: the purpose of any of these lip of proteins that
- 9:18Speaker 3: can be criminals is not to ruin your life or
- 9:21Speaker 3: give you heart disease. They're basically mailmen, right, So their
- 9:24Speaker 3: job is to deliver the mail primarily treadlist rides, and
- 9:27Speaker 3: go home at the end of the day, which is
- 9:29Speaker 3: the liver all right. Well, most mailmen aren't bad dudes, right,
- 9:32Speaker 3: But if that mailman you know, gets lost along the
- 9:34Speaker 3: way instead of delivering the mail, friends this truck in
- 9:37Speaker 3: your arterial wall, that's a bad mailman. And you've got
- 9:40Speaker 3: a corrupt workforce. And so we need to do something
- 9:42Speaker 3: about that. And so really a lot of my book,
- 9:45Speaker 3: I use a lot of metaphors. I use a lot
- 9:47Speaker 3: of catch phrases and things because one of my goals
- 9:51Speaker 3: has always meant to walk with kings but never lose
- 9:53Speaker 3: the common touch. And lipids get so complicated, so esoteric.
- 9:58Speaker 3: I love them. I learned things every single day. It's
- 10:01Speaker 3: wonderful and it's a beautiful, beautiful privilege to explore all
- 10:05Speaker 3: these wonderful, wonderful pathways. But at the same time, if
- 10:08Speaker 3: I can't communicate the things that hopefully I understand in
- 10:11Speaker 3: a relatable manner, then I'm no good And so I
- 10:15Speaker 3: you know, that's why I use a lot of these things.
- 10:16Speaker 2: And there's you know, pictures and graphics and all sorts.
- 10:19Speaker 3: Of things in my book that hopefully helps us make
- 10:22Speaker 3: better sense of the overall factors that lead to part attack,
- 10:26Speaker 3: strokes and dementia, how to mitigate those risks, and also
- 10:29Speaker 3: to make some sense of normal physiology at the same time.
- 10:33Speaker 1: Yeah, that's amazing, because I agree that lipids. I love
- 10:38Speaker 1: doctor day Springs so much. He's so knowledgeable about lipids,
- 10:41Speaker 1: just like you are. But sometimes reading through his stuff,
- 10:44Speaker 1: I get a little bit lost because I don't have
- 10:46Speaker 1: a background in lipids. You know, in pharmacy school it
- 10:49Speaker 1: was you know, LDL HDL, you know, just the basics.
- 10:53Speaker 2: We didn't really go beyond that.
- 10:55Speaker 1: In fact, I didn't really know about lipel protein little
- 10:57Speaker 1: A able lipel protein B until doctor day spring, which,
- 11:01Speaker 1: by the way, my dad did have checked, but his
- 11:03Speaker 1: results aren't back yet. I'm anxious to.
- 11:05Speaker 2: Hear about that.
- 11:07Speaker 1: But thank you for bringing this to light and also
- 11:09Speaker 1: making it easier for us to understand so that we
- 11:11Speaker 1: can understand it, but also better explain.
- 11:14Speaker 2: It to our own patients, who you know.
- 11:17Speaker 1: It is hard to explain these things to our patients
- 11:19Speaker 1: without getting geeked out in different terms or being able
- 11:23Speaker 1: to explain it in a way that anyone can understand.
- 11:26Speaker 1: So I love I love your metaphors.
- 11:28Speaker 2: It's amazing.
- 11:29Speaker 1: So now that you've kind of given us a little
- 11:31Speaker 1: bit of the framework, how is the cholesterol and the
- 11:33Speaker 1: brain different from the cholesterol in peripheral circulation.
- 11:38Speaker 2: Oh boy?
- 11:39Speaker 3: And so really it is supposed to be kept siloed
- 11:43Speaker 3: from the peripheral circulation, like I said, in the perfyle circulation,
- 11:46Speaker 3: you know, the ApoB containing lipoproteins or mailman, you know,
- 11:49Speaker 3: deliver the mail techosrides a few fossil lipids and then
- 11:53Speaker 3: go home to deliver at the end of the day.
- 11:55Speaker 2: And really in the brain though it's wildly different.
- 11:59Speaker 3: There's some of the same some of the same nomenclature
- 12:02Speaker 3: in the brain, but the characters are are vastly different.
- 12:06Speaker 3: And so the half life of cholesterol in the brain
- 12:09Speaker 3: is six months to five years.
- 12:10Speaker 2: Holy smokes. That is, uh has a long time, whereas
- 12:14Speaker 2: in the preffery, you know, it's a several days.
- 12:18Speaker 3: And in some of the particles, the VLDL, the IDL particles,
- 12:21Speaker 3: the kylo microns, they're gone in minutes to hours, you know,
- 12:24Speaker 3: those are quickly hydrolyzed, and then the LDL particles will
- 12:27Speaker 3: linger you know, a few days. HDL particles are around
- 12:31Speaker 3: a little bit longer than that. But the brain, oh wow,
- 12:33Speaker 3: you know, the half life cholesterol is much much longer.
- 12:36Speaker 2: That's kind of interesting. And twenty to twenty five percent
- 12:39Speaker 2: of our total body clusterols in the brain. Oh, that's
- 12:42Speaker 2: also interesting.
- 12:42Speaker 3: And so this is why there's a lot of concern
- 12:44Speaker 3: on you know, cholesterol and low cholesterol levels and various
- 12:48Speaker 3: medications as far as brain health, and there's some nuance
- 12:50Speaker 3: to that for sure, And so the brain is rather interesting.
- 12:55Speaker 3: And the what's supposed to happen in the brain is
- 12:58Speaker 3: the astrocyite is really supposed to in the adult brain
- 13:02Speaker 3: make the cholesterol, and then the cholesterol is exported out
- 13:06Speaker 3: into something called an apo e HDL like particle. So
- 13:12Speaker 3: we can call them basically HDL particles because they're in
- 13:14Speaker 3: that density range. Are they really HDLs now, but they're
- 13:17Speaker 3: in the same density range, whereas below the brain our
- 13:20Speaker 3: HDL particles typically have a po A one as the
- 13:23Speaker 3: primary structural lipe of protein. Already we're getting crazy here, right,
- 13:27Speaker 3: But under normal physiologic circumstances, your astrocite, you know, makes
- 13:31Speaker 3: the cholesterol. Okay, we got some cholesterol, and then it
- 13:34Speaker 3: exports it to the a POEHDL like particle. Then the
- 13:37Speaker 3: apoe HDL particle delivers it to the neuron, and then
- 13:41Speaker 3: neuron uses cholesterol for a litany of functions for synaptric transmission,
- 13:45Speaker 3: incorporates it into lipid raphs, and it's really essential for
- 13:47Speaker 3: the neuron to be able to do its work. Additionally,
- 13:50Speaker 3: cholesterol production is quite quite costly energetically. It takes a
- 13:55Speaker 3: lot of ATP and the cetylcoa and nadph to synthesize cholesterol,
- 14:00Speaker 3: and so the neuron has a lot of work to do. Right,
- 14:02Speaker 3: it's busy, it's the CEO. He's doing all sorts of stuff.
- 14:05Speaker 3: You know, at a busy medical office, he could be
- 14:07Speaker 3: the physician, right, and he's doing all sorts of stuff
- 14:09Speaker 3: he doesn't have. He doesn't really want to be synthesizing
- 14:12Speaker 3: clusterrawl and uses energy to do that. He wants to
- 14:14Speaker 3: have it on his desk, you know, sign the prior
- 14:16Speaker 3: off and go go on his merry way. And so
- 14:18Speaker 3: the astracite is kind of like that support staff. And really,
- 14:21Speaker 3: at a good medical practice or at a busy office,
- 14:24Speaker 3: you need everybody doing their parts in order for things
- 14:27Speaker 3: to be streamlined in order for things to work the
- 14:29Speaker 3: way they're supposed to. And so that's supposed to be
- 14:33Speaker 3: how it happens. However, in the context of neuroinflammation, that
- 14:39Speaker 3: process can go awry, and you know, if the neuron
- 14:42Speaker 3: isn't getting the clusterrawl delivered, the neuron can synthesize his
- 14:45Speaker 3: own apoe which is not good, and that's a sign
- 14:47Speaker 3: of a stress neuron, it can make its own cluster
- 14:49Speaker 3: awl and then but you know, that's a surefire sign
- 14:54Speaker 3: for inevitable burnout when the neuron who is orchestrating everything
- 14:58Speaker 3: else in life is having to do the job that
- 15:01Speaker 3: an astrocite or other cells in the CNS are having
- 15:05Speaker 3: to do.
- 15:05Speaker 2: And you can do it for a little bit, but
- 15:08Speaker 2: long term you're going to have some consequences.
- 15:10Speaker 3: And so that's a little bit of the brain cholesterol story.
- 15:15Speaker 3: And I know I teased you with a little a
- 15:18Speaker 3: Poe discussion, and I'm sure that that will probably follow,
- 15:21Speaker 3: But lipids in.
- 15:22Speaker 2: The brain are pretty wild. And one thing.
- 15:26Speaker 3: Before we get into the next the next adventure, is
- 15:30Speaker 3: apo B in the central nervous system.
- 15:31Speaker 2: Right.
- 15:33Speaker 3: ApoB is a five hundred and fifty kilo Dalton glycoprotein,
- 15:36Speaker 3: very big four and thirty six amino acids, so it.
- 15:39Speaker 2: Doesn't cross the blood brain barrier.
- 15:42Speaker 3: And it's been stated for a long time that there
- 15:45Speaker 3: is no apo B in the central nervous system. Well,
- 15:49Speaker 3: a couple of years ago, Picard and colleagues demonstrated that
- 15:52Speaker 3: there was ApoB president in the central nervous system in
- 15:55Speaker 3: certain people, and it was correlated with the presence of
- 16:00Speaker 3: phosphor related TAO, which is one of the hallmarks of
- 16:02Speaker 3: Alzheimer's disease, and so it can be there, it's not
- 16:05Speaker 3: supposed to be there. If it's there, that's problematic. But
- 16:09Speaker 3: you know, with with brain lipids, we're always learning things.
- 16:13Speaker 3: And I think Aristotle said the more you know, the
- 16:16Speaker 3: more you know you don't know. I think he was
- 16:18Speaker 3: talking about lipids actually, and so we're learning things every
- 16:23Speaker 3: day about that and having to sometimes shift our paradigms
- 16:27Speaker 3: based based on that.
- 16:29Speaker 1: Well, yeah, Doctor day Spring also alluded to the fact
- 16:34Speaker 1: that yeah, even because people get so concerned to me
- 16:37Speaker 1: in the pharmacy when they start a statin and they say, oh, no,
- 16:41Speaker 1: you know, if my LDL is this low, does that
- 16:44Speaker 1: mean I'm going to get Alzheimer's or you know that
- 16:46Speaker 1: you read different things. But what from what I understand
- 16:50Speaker 1: is your LDL and your periphery does not correlate with
- 16:53Speaker 1: cholesterol levels in your brain. So you cannot deduce it.
- 16:55Speaker 1: If you know you have a certain cholesterol level and
- 16:58Speaker 1: your periphery on your lipid panel, that does correlate anything
- 17:01Speaker 1: with what's going on in your brain.
- 17:02Speaker 2: Is that right?
- 17:05Speaker 3: You know this is interesting, and so okay, I'm going
- 17:10Speaker 3: to address this. I'm going to give you the three
- 17:13Speaker 3: big buckets of lipid disturbances in the brain, and then
- 17:16Speaker 3: I'm going to elaborate that based on what you just
- 17:18Speaker 3: said about cholesterol and the preferree correlating or not correlating
- 17:22Speaker 3: with what's going on in the central nervous system.
- 17:25Speaker 2: So in the.
- 17:25Speaker 3: Alzheimer's disease brain, we consistently see three lipid anomalies. And
- 17:30Speaker 3: at one point during my PAGD dissertation, I had about
- 17:33Speaker 3: one hundred and fifty different ligands and proteins and I
- 17:37Speaker 3: was like, all right, what's the big important one can
- 17:39Speaker 3: how can we make sense of this?
- 17:40Speaker 2: Does this really have a lot of relevance? You know?
- 17:42Speaker 2: And it was crazy, but I've kind of.
- 17:45Speaker 3: Narrowed it down in my framework to three big buckets.
- 17:49Speaker 2: Of lipid disturbances.
- 17:50Speaker 3: One thing we see in the Alzheimer's brain is defective
- 17:54Speaker 3: cholesterol transport. Okay, your ability to transport cholesterol from astrocite
- 17:58Speaker 3: to neuron is impaired.
- 18:00Speaker 2: One.
- 18:00Speaker 3: The second is impartability to eliminate cholesterol. Because if there's
- 18:04Speaker 3: cholesterol excess, well, we want to be able to get
- 18:06Speaker 3: rid of it, and the neuron has.
- 18:08Speaker 2: One way to do that.
- 18:09Speaker 3: He can turn exos cholesterol to something called twenty four
- 18:11Speaker 3: S hydroxy cholesterol and that can diffuse across the blow
- 18:15Speaker 3: brain barrier and then be cleared in the periphery. So, okay,
- 18:19Speaker 3: we have that decreased ability to rid ourselves of exoscholesterol.
- 18:24Speaker 3: But then the third anomaly is actually decreased cholesterol synthesis.
- 18:28Speaker 3: And so people that have Alzheimer's disease, we tip even
- 18:32Speaker 3: on autopsies, we see decreased cholesterol synthesis and all the
- 18:36Speaker 3: enzymes related to cholesterolsynthesis, and we see decreased desmostral, which
- 18:42Speaker 3: is the penultimate precursor two cholesterol in the brain, and
- 18:45Speaker 3: across the board we see decreased total brain cholesterol and
- 18:50Speaker 3: people with Alzheimer's disease And so hmm, okay, so does
- 18:54Speaker 3: that correlate with what's going on below the brain?
- 18:57Speaker 2: Well, maybe is the answer.
- 19:00Speaker 3: And I think that's what's encouraging to me, is we're
- 19:02Speaker 3: having better biomarkers, we're learning more things, and we're going
- 19:05Speaker 3: to be able to operate with nuance and precision in
- 19:07Speaker 3: the future.
- 19:09Speaker 2: And so the.
- 19:09Speaker 3: Cholesterol synthetic pathway is a thirty seven step process, so
- 19:14Speaker 3: many intermediates.
- 19:15Speaker 2: It's ridiculous, but.
- 19:18Speaker 3: It starts off linear and then you get to the
- 19:21Speaker 3: final linear product is something called squalen before it aromatizes
- 19:25Speaker 3: into something called lnosterol. And so a lo noostraol is
- 19:28Speaker 3: at first, you know, is the first ring structure because
- 19:30Speaker 3: there's four rings on a cholesterol molecule. And then the
- 19:33Speaker 3: nostral has a couple different choices. It can go to
- 19:36Speaker 3: something called lathosterol, which is the Candutch russele pathway, and
- 19:40Speaker 3: then there is something called desmostral, which is the block pathway.
- 19:43Speaker 3: And so the block pathway actually predominates in the brain,
- 19:46Speaker 3: and that's desmostraol, and then deesmostral can be converted to
- 19:49Speaker 3: clesterol from whereas below the brain the Candutch rustle pathway
- 19:53Speaker 3: seems to predominate. So everything's flipped in the brain. And
- 19:56Speaker 3: so Sato and colleagues actually tested does mostral levels in
- 20:04Speaker 3: people who had Alzheimer's disease and cognitive impairment in the
- 20:09Speaker 3: Helsinki Businessman Study as well as the Japanese Cohort, and
- 20:12Speaker 3: they found that the does mostral levels in the serum
- 20:15Speaker 3: actually correlated quite well with what the doesmostrals levels were
- 20:19Speaker 3: in the CNS, and it correlated quite well with cognitive decline.
- 20:25Speaker 2: So that's interesting.
- 20:26Speaker 3: So potentially, now this these studies weren't huge, okay, But
- 20:32Speaker 3: at the same time, is it possible that does mostral
- 20:35Speaker 3: could be a marker of cholesterol hypoproduction and could be
- 20:40Speaker 3: a prognosticator of people who have decreased cholesterol synthesis in
- 20:44Speaker 3: the central nervous system and could go on to have
- 20:46Speaker 3: cognitive decline. I think it's possible, and so I think
- 20:49Speaker 3: does mostral is a great test. Does mostral and lethostral
- 20:53Speaker 3: your markers of cholesterol production, whereas campestral and psychostol are
- 20:58Speaker 3: your markers of cholesterol absorption? And Boston Heart Diagnostics does
- 21:01Speaker 3: run those tests, And so if you have an ability
- 21:04Speaker 3: to run those, it cannot only give you nuance when
- 21:07Speaker 3: it comes to potentially what you're seeing with somebody who
- 21:11Speaker 3: has a complaint of cognitive impairment, but it can also
- 21:14Speaker 3: help I think you operate with nuance if you're selecting
- 21:16Speaker 3: lipid lowering therapies, because let's say somebody is a hyper
- 21:19Speaker 3: absorber at baseline, Well, that person, you might actually reach
- 21:22Speaker 3: for a zetimibe, you know, right off the bat, rather
- 21:25Speaker 3: than you know, just go with the statin, you know,
- 21:27Speaker 3: if they have elevated campestral and or psyitosterol. So it's
- 21:31Speaker 3: an interesting thing. And so basically does it correlate well?
- 21:35Speaker 3: Does mostral seems to quite well? And you know, is
- 21:39Speaker 3: that the be all end all? No, but I think
- 21:41Speaker 3: it potentially could be part of what we look at.
- 21:45Speaker 3: It's something that I would look at when I was
- 21:47Speaker 3: in clinic if somebody was complaining of you know, cognitive impairment,
- 21:53Speaker 3: and or if I was concerned that their their response
- 21:58Speaker 3: to typically a statin was was quite robust. If if
- 22:02Speaker 3: I saw the does mostral levels trending quite low? And
- 22:04Speaker 3: this is not you know, evidence based or something, this
- 22:07Speaker 3: is just you know, biochemistry base and and doctor day
- 22:11Speaker 3: Springs has said similar things. I would be inclined to
- 22:14Speaker 3: use combo therapy and I'm a big combo therapy fan anyway,
- 22:17Speaker 3: just because you know, the maximum if you if you
- 22:19Speaker 3: use a statin, the maximum you know, reduction in LDL
- 22:22Speaker 3: cholesterol is going to be with your initial dose, you know,
- 22:26Speaker 3: and so any subsequent doubling you're going to get you know,
- 22:30Speaker 3: maybe six percent additional LDLC lowering, but you're going to
- 22:33Speaker 3: increase the side effects quite a bit.
- 22:35Speaker 2: And I'm not big on you know, side effects.
- 22:38Speaker 3: I think if you're going to use a tool, it's
- 22:40Speaker 3: it's good to you know, maximize the efficacy of that
- 22:43Speaker 3: tool without you know, just leading to off target problems.
- 22:46Speaker 2: And you know, and one example of that is, you know,
- 22:49Speaker 2: nuance of diabetes.
- 22:51Speaker 3: So when you use a modern intensity statin let's say
- 22:53Speaker 3: we're suo stat in five milligrams for instance, you know
- 22:56Speaker 3: you're gonna have a ten percent increase risk of diabetes
- 22:59Speaker 3: over five years recent meta analysis versus high intense statin
- 23:03Speaker 3: thirty six percent HM. That's a lot. That's not a
- 23:07Speaker 3: trivial increase. But at the same time, how could I
- 23:10Speaker 3: get better LDLC reduction? I could upfront use you know,
- 23:13Speaker 3: the lower dose statin plus' ztam. I actually get better
- 23:17Speaker 3: LDLC reduction with that combo.
- 23:19Speaker 2: I minimize the side effects, the tolerability is better.
- 23:22Speaker 3: And you know, there's a few studies over in Europe
- 23:25Speaker 3: where they've used this approach post PCI and there was
- 23:28Speaker 3: some you know, decrease in recurrent events there.
- 23:31Speaker 2: So it's interesting.
- 23:32Speaker 3: I think the paradigm is also shifting the combination therapy.
- 23:36Speaker 3: Knowing that we have multiple ways to address this issue.
- 23:40Speaker 3: If the goal is to get you living in a safe,
- 23:42Speaker 3: relate lip in neighborhood, Hey, let's think about using multiple
- 23:45Speaker 3: tools in our toolbox rather than just you know, relying
- 23:49Speaker 3: on the king cong dose of the statin if it
- 23:52Speaker 3: was two thousand and four, absolutely right, because it was
- 23:54Speaker 3: kind of like Statin's and prey.
- 23:56Speaker 2: I think you should always pray.
- 23:57Speaker 3: But at the same time, we've got other tools if
- 23:59Speaker 3: there's an need to get you living in a safer
- 24:01Speaker 3: lipid neighborhood. And so anyway that was that was a
- 24:05Speaker 3: long tangential thing. But it's possible that this mastraol could
- 24:09Speaker 3: be a marker that correlates well crum wise with what's
- 24:13Speaker 3: going on in the CNS. Obviously, there's always things to
- 24:17Speaker 3: continue to learn, and there's other biomarkers that could be
- 24:20Speaker 3: helpful as well. But at the at the end of
- 24:23Speaker 3: the day, I think it's a knowing that we know
- 24:26Speaker 3: exactly what we're doing below the brain with our lipid
- 24:28Speaker 3: loring tools. Knowing that there's only one of those lipid
- 24:30Speaker 3: loring tools that does cross the blood brain barrier, which
- 24:32Speaker 3: would be the statin. I think it's just good to
- 24:36Speaker 3: use those in combination until we find out who's the
- 24:40Speaker 3: person who maybe we should use a higher dose statin
- 24:43Speaker 3: in the brain. Maybe if they have XSA BOB in
- 24:45Speaker 3: the CNS, maybe that's a person that could upset. We
- 24:47Speaker 3: don't know these things. At the population level. Statins don't
- 24:50Speaker 3: increase the risk of dimension.
- 24:51Speaker 2: We know that.
- 24:52Speaker 3: But I think that we're looking at individualized treatment and precision,
- 24:56Speaker 3: and you know, knowing a few more things about what's
- 24:59Speaker 3: going on in biomarker realm, I think is going to
- 25:01Speaker 3: help us better understand what combination of therapies, if necessary,
- 25:07Speaker 3: is going to be useful to mitigate people's cognitive decline.
- 25:10Speaker 1: Yeah, I'm glad you brought up the combination therapy. I
- 25:14Speaker 1: My dad actually went to the cardiologist last week and
- 25:18Speaker 1: they put him on a statin, which is fine. They
- 25:21Speaker 1: put him on a torbois statin and they didn't put
- 25:23Speaker 1: him on high dose, which I was kind of surprised
- 25:25Speaker 1: by but also grateful for, because his hemoglobin A one
- 25:28Speaker 1: C is already in the pre diabetes range. Okay, but
- 25:33Speaker 1: I questioned, why not add a zenamibe with the torbos statin,
- 25:38Speaker 1: and when I questioned it, the nurse called me back
- 25:40Speaker 1: and said, the cardiologist says, we want to maximize the
- 25:43Speaker 1: dose of the atobis statin first before adding on a zetamne.
- 25:47Speaker 1: And so I said, well, how can I, you know,
- 25:50Speaker 1: get the cardiologists some more information or studies on the
- 25:53Speaker 1: benefits of combination therapy being just as effective as high
- 25:57Speaker 1: dose statins with a lower rate of side effects.
- 26:00Speaker 2: So she gave me an email.
- 26:01Speaker 1: Address, and so I sent some information over and that
- 26:05Speaker 1: annoying patient, but I do want to prescribe as that
- 26:08Speaker 1: am I'm with as a tortoist stat with his high score.
- 26:11Speaker 1: So I'm glad you brought that up. I think there's
- 26:14Speaker 1: something we underutilize and I don't know why. From everything
- 26:18Speaker 1: I've read, it's all out there about combination therapy, but
- 26:21Speaker 1: it's not used very much in practice. I still see
- 26:23Speaker 1: ninety eight year old nursing home patients on eighty milligrams
- 26:27Speaker 1: of a tourist stat and I just, you know, why
- 26:30Speaker 1: are we doing this to these people?
- 26:32Speaker 3: But yeah, I'm one hundred percent in agreement with you, you know,
- 26:39Speaker 3: outside of a q coorinat syndrome. There really isn't strong
- 26:43Speaker 3: data to be using, you know, just high intensity stat
- 26:46Speaker 3: and model therapy.
- 26:46Speaker 2: There really isn't. And we have so many tools these days.
- 26:50Speaker 3: And I'm sure you probably sent them the racing trial,
- 26:52Speaker 3: you know, showing that the combination of modern intensity stampolds
- 26:56Speaker 3: that a my I was better tolerated. You know, there
- 26:58Speaker 3: was less diabetes over time, better adherence, better LDLC reduction,
- 27:02Speaker 3: you know.
- 27:02Speaker 2: And so you know, we have a lot of data now.
- 27:04Speaker 2: It's not like we're just messing around and being theoretical.
- 27:07Speaker 2: Now the data is there. And I think that this.
- 27:11Speaker 3: Cardiologist hopefully we'll read my book here how when it
- 27:14Speaker 3: comes out here in a few weeks, and yeah, he'll
- 27:18Speaker 3: become combophilic, you know, because you know there's all this
- 27:21Speaker 3: you know, we can talk about hydrophilic statins and life
- 27:23Speaker 3: pophilic statins. Let's just be combophilic and use our multiple
- 27:27Speaker 3: tools in the toolbox, because I think we can more
- 27:30Speaker 3: safely and effectively get people living in a safer lipid
- 27:33Speaker 3: neighborhood if they need to since they've been broken into,
- 27:37Speaker 3: without jeopardizing their home security system, right and their quality
- 27:40Speaker 3: of life. Because you know, pillar one of my home
- 27:43Speaker 3: security system is normal parameters of glucose metabolism, i e.
- 27:47Speaker 3: Not having diabetes, not having insular resistance and all. That's
- 27:50Speaker 3: a continuum, right. It's kind of like being you know,
- 27:53Speaker 3: mostly pregnant or almost pregnant and I are aren't. You know,
- 27:56Speaker 3: it's just a matter of how far along you are
- 27:57Speaker 3: in that process. And if we can do things to
- 28:00Speaker 3: minimize you know, the side effects there in any way,
- 28:04Speaker 3: well why don't we do that? And we can, and
- 28:06Speaker 3: I you know, I'm I'm a big fan of you know,
- 28:09Speaker 3: the upfront, you know, lower dose stat and pulls a
- 28:11Speaker 3: zetemi combo.
- 28:12Speaker 2: You get really good results.
- 28:14Speaker 3: And it's one of those things where if you are
- 28:17Speaker 3: living in a neighborhood where you've been broken into, your
- 28:19Speaker 3: body fights you tooth and nail to stay in that
- 28:22Speaker 3: rough neighborhood. You know, this is home, darn it. And
- 28:26Speaker 3: so when you use a statin and you decrease cholesterol synthesis,
- 28:29Speaker 3: your body is smart and it increases its absorption. Well,
- 28:32Speaker 3: how can we decrease absorption, Well, let's just tack on
- 28:35Speaker 3: a zetemi additionally. You know, if there's a need to
- 28:38Speaker 3: get people to a lower LDLC target, well, what do
- 28:41Speaker 3: statins do to PCSKN nine levels. Well, a TORP stat
- 28:44Speaker 3: in eighty increases PCSK nine forty six percent. H What
- 28:48Speaker 3: does PCSK nine do well, it degrades your LDL receptors. Well,
- 28:52Speaker 3: you could tack on you know, and PCs canine inhibitor.
- 28:55Speaker 3: They all work really well together in synergy. It doesn't
- 28:58Speaker 3: have to be a choose one or the other. Their
- 29:00Speaker 3: third party payers will say otherwise. But from a mechanistic standpoint,
- 29:04Speaker 3: from a biochemical homeostasis standpoint, the tools we have.
- 29:08Speaker 2: Work really really well together in combo.
- 29:11Speaker 3: And it's unfortunate that too often, I think people are
- 29:15Speaker 3: still worshiping at the altar of high intensity statins when
- 29:20Speaker 3: we really can, I think, more smartly and safely get
- 29:25Speaker 3: people living in a safer lipid neighborhood.
- 29:27Speaker 1: Yeah, I agree. So one thing you said is that
- 29:30Speaker 1: at a population level, statins don't increase the risk of Alzheimer's.
- 29:34Speaker 2: Is there a biomarker that can be checked.
- 29:36Speaker 1: That would, on an individual therapy level say that you
- 29:41Speaker 1: might have a higher risk of Alzheimer's with a statin.
- 29:44Speaker 1: Is there that biomarker available or is that not a
- 29:46Speaker 1: thing yet?
- 29:48Speaker 3: I think from a lipid standpoint, does mostol is a
- 29:52Speaker 3: nice thing to run as far as hey are we
- 29:54Speaker 3: concerned about having decreased production given that it does correlate
- 29:58Speaker 3: quite well with production and the central nervous system, and
- 30:02Speaker 3: so we can potentially use that and we probably need
- 30:05Speaker 3: just larger studies with more biobanks there are there are
- 30:09Speaker 3: Alzheimer's specific biomarkers that are that are really encouraging, you know,
- 30:13Speaker 3: p TAW two seventeen and the amyloid beta forty two
- 30:16Speaker 3: to forty ratio. Those have actually been demonstrated to correlate
- 30:19Speaker 3: quite well with some of the imaging lately.
- 30:21Speaker 2: So that's that's improving all the time.
- 30:24Speaker 3: I mean, substrate utilization across the lifespan is huge as
- 30:27Speaker 3: far as the risk associated with diabesity and hypertension and
- 30:33Speaker 3: all these you know, basically my home security system framework, Well,
- 30:37Speaker 3: we need to do everything we can to maximize that,
- 30:40Speaker 3: you know, obviously across the lifespan for all of us.
- 30:45Speaker 3: But I think that what is something that we probably
- 30:47Speaker 3: ought to know is our apoe genotype, and I think
- 30:51Speaker 3: that can help us also act with with some nuance.
- 30:55Speaker 3: And I think that's probably a good segue into a
- 30:58Speaker 3: poe and so ao E below the brain is sixteen
- 31:03Speaker 3: to ninety percent of HDL particles have a POE on them,
- 31:07Speaker 3: and then apoe can be transferred from HDL particles to
- 31:11Speaker 3: APO B particles. And what ABOE does is it's kind
- 31:14Speaker 3: of an access card to the liver. So if a
- 31:17Speaker 3: particle has a bo E on it, it's going to
- 31:19Speaker 3: an a bo B particle has a po E e
- 31:21Speaker 3: for easy access, the liver will readily uptake it and
- 31:24Speaker 3: it will help clear the lipe of.
- 31:25Speaker 2: Protein under normal physiologic circumstances. All right, that seems fine now.
- 31:30Speaker 3: In the brain though, abo E is the predominant cholesterol
- 31:34Speaker 3: particle that's delivering clusterol from astercite to neuron.
- 31:37Speaker 2: So you and.
- 31:38Speaker 3: I, all of us have we inherit one copy of
- 31:41Speaker 3: a poe from each parent.
- 31:43Speaker 2: So apoe G is on chromosome nineteen.
- 31:46Speaker 3: It's and it's actually really close to something called a
- 31:50Speaker 3: po C one, which is which is another interesting limpid
- 31:53Speaker 3: character that we haven't quite figured out what to do with.
- 31:56Speaker 3: But anyway, so apo e's on chromosome nineteen, and so
- 32:01Speaker 3: most people have two copies of what's called apo E three.
- 32:05Speaker 3: So the wild type, which would be the most common
- 32:07Speaker 3: type would be a three three. So seventy five percent
- 32:10Speaker 3: of people have a three three. Uh, and then about
- 32:12Speaker 3: fourteen percent of people have one copy of a po
- 32:15Speaker 3: E four, and then about two percent of people have two.
- 32:18Speaker 2: Copies of a po E four. And the most well.
- 32:21Speaker 3: Known person who is a homozygo for a POB four
- 32:23Speaker 3: is Chris Hemsworth, So APO E four you know, maybe uh,
- 32:27Speaker 3: since his character that he plays in the in the
- 32:31Speaker 3: Avengers and so anyway, but yeah, so he has two
- 32:33Speaker 3: copies of a POB four, and so people with one
- 32:36Speaker 3: copy of a po E four have about a you know,
- 32:42Speaker 3: three to four fold risk of Alzheimer's disease at baseline,
- 32:45Speaker 3: no other factors being considered, whereas people with two copies
- 32:49Speaker 3: of a po E four maybe about twelve x Ooh okay,
- 32:52Speaker 3: So now here's the thing.
- 32:54Speaker 2: And then there's a POE.
- 32:55Speaker 3: Two which isn't as common, and that's that's a different conversation,
- 32:59Speaker 3: more relegated for lipid geeks who want to talk about
- 33:02Speaker 3: type three dispbata lipoproteinemia, which you can if you want,
- 33:05Speaker 3: but anyway, so but it's really the APO E four
- 33:08Speaker 3: that has been identified as the number one genetic risk
- 33:10Speaker 3: factor for Alzheimer's outside of the autosomal dominant mutations in
- 33:15Speaker 3: APP and pre sinnel and one. Those are really rare,
- 33:18Speaker 3: really accelerated early Alzheimer's, and that's really really rare.
- 33:22Speaker 2: But for the general population, APO E four is the
- 33:25Speaker 2: number one genetic risk factor. Okay. So I think it's
- 33:29Speaker 2: useful to know. I mean, that doesn't change.
- 33:31Speaker 3: I think it's good to know your apoe genotype and
- 33:35Speaker 3: use This used to be contentious. People would say, all,
- 33:37Speaker 3: I don't want to know. But it's not a deterministic gene.
- 33:39Speaker 3: This isn't like, you know, Huntington's disease like where it's like, okay,
- 33:42Speaker 3: if you have this illele, you're going to end up
- 33:45Speaker 3: with this horrible, horrible, you know, neurodegenerative condition. But it
- 33:50Speaker 3: tells you that you have less margin for you know,
- 33:53Speaker 3: and I think I would want it.
- 33:55Speaker 2: I mean, I do know.
- 33:56Speaker 3: I thankfully I have a three three okay, not interesting.
- 33:58Speaker 3: My wife, though, has one cop of APO E four. Okay,
- 34:02Speaker 3: good to know. So I think that here, you know,
- 34:05Speaker 3: if if your fire department is defective, so to speak,
- 34:08Speaker 3: well just don't let fires start. Is the best way
- 34:11Speaker 3: to go about this and be preventive. And it just
- 34:14Speaker 3: tells you, hey, you know, I have less margin for
- 34:18Speaker 3: error when it comes to you know, actually metabolic health.
- 34:22Speaker 3: And I would say things like, you know, alcohol usage
- 34:25Speaker 3: and things along those lines that you know is not
- 34:27Speaker 3: going to be probably as critical to be quite.
- 34:29Speaker 2: As spartan and monastic.
- 34:31Speaker 3: Uh, if you have a three three copy or a
- 34:34Speaker 3: two three, whereas when you have a copy of ApoB
- 34:37Speaker 3: four or two copies, I think you're you have less
- 34:39Speaker 3: margin for error because the last thing you want to
- 34:42Speaker 3: do is in.
- 34:43Speaker 2: Your terminal decade. Uh, just not be you anymore. There's
- 34:47Speaker 2: a big difference between living and existing.
- 34:49Speaker 3: And my grandmother just passed away from Alzheimer's and it's
- 34:52Speaker 3: super sad.
- 34:53Speaker 2: It's super super sad.
- 34:55Speaker 3: And you know, for as long as the Good Lord
- 34:57Speaker 3: keeps you around, on to be crushing it, cognit and
- 35:00Speaker 3: then then be done, you know. And I think that
- 35:01Speaker 3: that would be the case for anybody. And so I
- 35:04Speaker 3: really do believe that, you know, getting ahead of the
- 35:09Speaker 3: game for all these things, whether it be caribasker disease,
- 35:12Speaker 3: whether it be brain health, is of paramount of importance.
- 35:16Speaker 3: And I think that you know, just knowing your apoe
- 35:18Speaker 3: genotype is a useful thing to know.
- 35:22Speaker 1: Yeah, I agree. So I do a lot of pharmacogenomic
- 35:24Speaker 1: testing for patients, and so I've tested probably two hundred
- 35:28Speaker 1: and fifty patients now and I'm an E three E three,
- 35:32Speaker 1: so thankfully. But I do have a handful of patients
- 35:36Speaker 1: where I've tested they do have a copy of the EPHOR,
- 35:38Speaker 1: and I do have also a handful that have two
- 35:41Speaker 1: copies of ephor.
- 35:42Speaker 2: Interestingly, most of the.
- 35:44Speaker 1: Patients that are two copies of ephor are in a
- 35:47Speaker 1: dementia unit of a nursing home. That so it's been
- 35:51Speaker 1: interesting that way. But I have worked with people in
- 35:53Speaker 1: the community who have ephoor e foor too, and I
- 35:56Speaker 1: do tell them, you know, it's important to know and
- 35:58Speaker 1: then mitigate those risks. And one of the risks you
- 36:01Speaker 1: know that you mentioned is insulin resistance. So I want
- 36:07Speaker 1: to ask you this because in the community, I see
- 36:10Speaker 1: a lot of patients with diabetes. If their A one
- 36:12Speaker 1: and C is in the pre diabetes range. I don't
- 36:14Speaker 1: see a lot of providers treat that. I just see
- 36:18Speaker 1: them monitor it and then they end up getting you know,
- 36:22Speaker 1: diabetes after some time. But what it helped mitigate the
- 36:25Speaker 1: risk if a person with you know, a pre diabetes
- 36:29Speaker 1: a one C was started on a mat format or
- 36:31Speaker 1: something to prevent the full blown diabetes, but that also
- 36:34Speaker 1: reduce their risk of Alzheimer's.
- 36:38Speaker 3: Yeah, and so I think that, you know, if you're
- 36:41Speaker 3: trending in the wrong direction when it comes to insular resistance.
- 36:44Speaker 3: You know, nobody ever said, boy, I wish I was
- 36:46Speaker 3: more insular resistant. You know, I wish I had more
- 36:49Speaker 3: glucose excursions. And I mean glucose is is critical and
- 36:52Speaker 3: in the brain in particular. Right, if you and I
- 36:54Speaker 3: just didn't eat for three or four days, you know,
- 36:57Speaker 3: our blood glucose would be around you know sixty to seven. Why, well,
- 37:01Speaker 3: a padic glucnean genesis and you have a glute one
- 37:04Speaker 3: transporter to passively diffuse glucose into the brain. The brain
- 37:08Speaker 3: is incredibly important substrate. Now, can it use you know,
- 37:11Speaker 3: key tones, yes, Can it use glucose drive black date yes?
- 37:14Speaker 3: But you know, glucose is really is money for the
- 37:17Speaker 3: neurons and you need it. And so the more efficient
- 37:20Speaker 3: that you can be with your substrate utilization, with your
- 37:23Speaker 3: ability to utilize glucose, the better off. Right, fatty acids
- 37:27Speaker 3: are your savings account, and below the brain we should
- 37:29Speaker 3: be using our savings account. But unfortunately, you know, glucose
- 37:32Speaker 3: with are dollar bills. People are way too relian on
- 37:34Speaker 3: the dollar bills. And half the time they don't even
- 37:36Speaker 3: use the dollar bills. They're frumbleing around their wallet and
- 37:38Speaker 3: dropping it. You know, that's insular resistance. And so if
- 37:40Speaker 3: we can be efficient and utilize our savings account withdraw
- 37:43Speaker 3: from our savings account most of the time below the brain,
- 37:45Speaker 3: we can preserve the dollar bills for the brain, and
- 37:49Speaker 3: then I don't think we're going to have those neuroinflammatory
- 37:52Speaker 3: fires start. And so I'm all for getting ahead of
- 37:55Speaker 3: the game. Pre diabetes and diabetes to me are really
- 37:58Speaker 3: the same entity. It's just a matter of how far
- 38:00Speaker 3: along you are even before that. I'm a big fan
- 38:03Speaker 3: of getting a fasting insulin, you know, and a home IR.
- 38:07Speaker 3: So if you get your fasting insulin multiply by your
- 38:09Speaker 3: fasting gluecose divide by four oh five, you know, you
- 38:11Speaker 3: get what's called your homa IR. And if it's over too,
- 38:15Speaker 3: you're a real insulin resistant. We need to do something
- 38:17Speaker 3: about that. Additionally, if you really get granular. With advanced
- 38:20Speaker 3: lipid panels, you can identify insular resistance even prior to
- 38:26Speaker 3: you know, having a fasting, insulin be elevated. My wife
- 38:29Speaker 3: was a good example of that, and so she had
- 38:31Speaker 3: a lot of small dense el Deal particles, which there
- 38:34Speaker 3: are rare genetic exceptions that will make you have elevated
- 38:36Speaker 3: small dense el Deal particles, but in general that's a
- 38:39Speaker 3: sign of insulin resistance. Jerry Schulman at Yale has it's
- 38:42Speaker 3: done some really elegant work showing that the first sight
- 38:45Speaker 3: of insulin resistance is skeletal muscle. And so she wasn't
- 38:48Speaker 3: exercising at the time. After three months of just exercise
- 38:51Speaker 3: combination aerobic resistance training, her overall particle count dropped from
- 38:55Speaker 3: around thirteen hundred to less than one thousand, and her
- 38:59Speaker 3: small dense deal particles, which were elevated, completely normalized. And
- 39:02Speaker 3: that was without any really shift in her diet. You know,
- 39:05Speaker 3: she was still eating way too many dino chicken nuggets,
- 39:07Speaker 3: I think, but you know, she was just that's the
- 39:10Speaker 3: that's the magic of movement. You know, motion is lotion,
- 39:12Speaker 3: movement is medicine, whatever you want to say, but really,
- 39:15Speaker 3: you know, that's that's where insular.
- 39:16Speaker 2: Resistet starts a skeleton muscle.
- 39:18Speaker 3: And so that's why I think that for prevention purposes,
- 39:21Speaker 3: I mean, there's nothing like exercise, and there's so many
- 39:24Speaker 3: different mechanisms as far as you know, increasing brain drive,
- 39:27Speaker 3: neurotrophic factor, and increasing hippocampal volume, and you know, all
- 39:31Speaker 3: these other things that have been associated with decreased cognitive climb.
- 39:36Speaker 3: But probably more than anything, it's just substrate utilization. You're
- 39:39Speaker 3: using your fuel efficiently, you know, because when you're not
- 39:42Speaker 3: using your fuel efficiently, you're asking for trouble. And most
- 39:46Speaker 3: of our chronic inflammatory conditions in your are over nutrition
- 39:51Speaker 3: society is just due to excess visceral adipucity, you know.
- 39:56Speaker 2: And that and this is an interesting topic.
- 40:01Speaker 3: As far as inflammation, right, you know, inflammation, it's better
- 40:05Speaker 3: to not be inflamed, right uh, you know, and noia
- 40:07Speaker 3: ever says boy, I wish I was more inflamed, you know,
- 40:10Speaker 3: but inflammation, it's important to get to the root cause
- 40:12Speaker 3: of inflammation. And in most people, so certain people have
- 40:16Speaker 3: r A or chrome's, you know, some of these systemic
- 40:18Speaker 3: inflammatory conditions, you know, and if you have you know, right,
- 40:22Speaker 3: lower quadrant pain, and you weren't previously having that, Well,
- 40:25Speaker 3: you know, pendicitis and that's why your CRP is through
- 40:27Speaker 3: the you know, so go get that tink care of.
- 40:29Speaker 3: But at the same time, most people who have an
- 40:32Speaker 3: elevated HSCRP, which is our most common, widely available you know,
- 40:36Speaker 3: biomarker for for inflammation and it is an independent risk
- 40:40Speaker 3: factor for cardive maaster disease. Well why is that, Well,
- 40:44Speaker 3: it's generally because of angry fat and so well, if
- 40:49Speaker 3: we can do something about that, which is regulate your
- 40:52Speaker 3: insulin sensitivity and restore your metabolic arrangements, we're going to
- 40:55Speaker 3: see a nice reduction in that HSCRP. And one of
- 40:59Speaker 3: the things that's really cool about the incretin therapies, right,
- 41:03Speaker 3: you know the GLP W interceptor agonists and you know
- 41:05Speaker 3: things like turs eppetite as well. They actually take your
- 41:09Speaker 3: macrophages and shift them from an M one pro inflammatory
- 41:13Speaker 3: phenotype to an M two anti inflammatory phenotype. Even your
- 41:16Speaker 3: macrophages are it's important for them to utilize fuel appropriately.
- 41:21Speaker 3: So M one pro inflammatory macrophages are over reliant on
- 41:25Speaker 3: glycolysis the dollar bills, whereas M two anti inflammatory macrophages
- 41:30Speaker 3: are reliant on fatty acids for their fuel. Fatty acid
- 41:33Speaker 3: oxidation is their predominant fuel source. And so what those
- 41:36Speaker 3: agents do is they shift your inflammatory cells from a
- 41:41Speaker 3: pro inflammatory one to an anti inflammatory one. And that's
- 41:44Speaker 3: why if you and I, you know, it was great
- 41:46Speaker 3: to see my patients who had elevated HSCRP, you know,
- 41:49Speaker 3: after we would use some magnetide or something like that
- 41:51Speaker 3: for a few months and they had you know, they're
- 41:53Speaker 3: feeling great, they're crushing into life.
- 41:54Speaker 2: Now their HSCRP would go down significantly.
- 41:57Speaker 1: Wow.
- 41:58Speaker 3: Yeah, and that's really cool. And the same thing does
- 42:01Speaker 3: happen in microglia. And one of the things that you
- 42:04Speaker 3: know happens in in microglia the immune cells of the brain,
- 42:07Speaker 3: is that they get really really annoyed, you know, especially
- 42:11Speaker 3: when your fuel isn't being utilized properly and cholesterol isn't
- 42:15Speaker 3: being transported appropriately. Microglia become reactive and they become pro inflammatory.
- 42:22Speaker 3: And there's some preliminary data I think they still need
- 42:24Speaker 3: to tease that out on the same sort of thing
- 42:26Speaker 3: happening with those GLP one receptor agonists even in the microglia,
- 42:31Speaker 3: and there's some real benefit that's being shown in the
- 42:34Speaker 3: neurovascular unit with those with those agents too. So could
- 42:37Speaker 3: that be part of a cocktail for metabolic and lipids
- 42:41Speaker 3: for mitigating cognitive decline?
- 42:42Speaker 2: I think is possible.
- 42:44Speaker 3: And so it's all about substrate utilization and getting to
- 42:47Speaker 3: the nitis of inflammation rather than just you know, let's
- 42:50Speaker 3: all take hyboprofen for you know, both cardiac disease and
- 42:53Speaker 3: dementia prevention.
- 42:53Speaker 2: Well, probably not.
- 42:55Speaker 3: And another example of this that I think that the
- 42:57Speaker 3: context really matters with inflammation is this people group called
- 43:01Speaker 3: the Shimona in Bolivia. So these guys are hunter gathers.
- 43:05Speaker 3: Their baseline HSCRP mean is nine point two. Holy smokes, right,
- 43:11Speaker 3: anything over two, I mean that's independent risk factor for
- 43:14Speaker 3: cardiovascar disease. Oh shoot, nine point two. So you must think, oh,
- 43:18Speaker 3: these people have raging heart disease. Do I have any
- 43:21Speaker 3: heart disease? Why do they have elevated HSCRP because they're
- 43:25Speaker 3: riddled with parasites. And so it's a matter of Okay,
- 43:28Speaker 3: if you have inflammation, why is it happening? You know,
- 43:31Speaker 3: a lack of inflammation, you're going to be susceptible to
- 43:33Speaker 3: all sorts of infections and things.
- 43:35Speaker 2: These people, you.
- 43:36Speaker 3: Know, they live in an area where the water isn't
- 43:38Speaker 3: isn't very good, and you know they're riddle of parasites.
- 43:41Speaker 3: So that HSCRP, which actually has a panameric and a
- 43:44Speaker 3: monomeric form two which we can't blood testing. Interestingly, you
- 43:49Speaker 3: know their CRP is just eradicating para parasites, good for them.
- 43:53Speaker 3: And fascinatingly, even people with a POE four copies tend
- 43:57Speaker 3: to nagat Alzheimer's and the shimina And it was actually
- 44:00Speaker 3: there's one twenty seventeen study where they did cognitive testing
- 44:04Speaker 3: on them and it was actually the APOE four people
- 44:07Speaker 3: that actually had better scores in that population. So once
- 44:10Speaker 3: again it's context that matters. I think when your body
- 44:13Speaker 3: resents its state of chronic overnutrition, then yeah, you know
- 44:17Speaker 3: eight Poe four becomes really really meaningful, super super bad news.
- 44:21Speaker 3: You have less margin for error. However, in the context
- 44:24Speaker 3: of appropriate substrate utilization across the lifespan, I think that
- 44:28Speaker 3: you know your your genes are not your destiny. Kelly
- 44:31Speaker 3: and neotis who's brilliant. You should have her on the show.
- 44:33Speaker 3: She's a preventive neurologist. She's absolutely fantastic. I've never met
- 44:36Speaker 3: her in person, but I've listened to her stuff.
- 44:38Speaker 2: She's brilliant. But you know, she says, your genes are
- 44:40Speaker 2: not your destiny.
- 44:41Speaker 3: I one hundred percent agree, especially when it comes to
- 44:44Speaker 3: cognitive health. And I think that anything that we can
- 44:47Speaker 3: do to maximize our you know, parameters of glucose metabolism, honestly,
- 44:52Speaker 3: the home security system framework in my in my you know,
- 44:57Speaker 3: in my paradigm, and then also looking at all other
- 45:00Speaker 3: factors as far as you know, your your lipids and
- 45:03Speaker 3: making sure we're getting ahead of the game on cardiovascular
- 45:05Speaker 3: health is essential. And you know, I think if we
- 45:09Speaker 3: really take the same preventive approach across the board, we're
- 45:12Speaker 3: going to see a huge decrease in not only coronary disease,
- 45:16Speaker 3: but also in Alzheimer's disease and other types of dementia.
- 45:20Speaker 1: Yeah, I'm glad that you end with giving everyone hope
- 45:24Speaker 1: because I do feel like when we talk about dementia,
- 45:27Speaker 1: when you talk about Alzheimer's disease, people feel like the
- 45:30Speaker 1: outlook is kind of bleak. But the way you said
- 45:33Speaker 1: it is you feel that it's hopeful, and you want
- 45:36Speaker 1: to make sure that our listeners have hope. Also that
- 45:39Speaker 1: we're knowing more and more about Alzheimer's all the time,
- 45:43Speaker 1: and there are things that we can do to prevent
- 45:45Speaker 1: Alzheimer's that you allude to in your book, the home
- 45:48Speaker 1: security system, including blood pressure control, you know, decreasing insulin resistance.
- 45:55Speaker 1: What we're the two other.
- 45:56Speaker 3: Ones again, So my home security system has four basic pillars.
- 46:01Speaker 3: Normal blood glucose, which is parameters of glucose metabolism, you know,
- 46:03Speaker 3: not being insular resistant.
- 46:05Speaker 2: Pilar two is normal blood pressure.
- 46:08Speaker 3: Pillar three is keep inflammation low, and that's you know,
- 46:11Speaker 3: and now you're like, well what about the shimine. Well
- 46:14Speaker 3: they have a good reason to be inflamed and they
- 46:16Speaker 3: have perfect glucose metabolism.
- 46:18Speaker 2: So ha. But and then pillar four is don't smoke
- 46:21Speaker 2: or do drugs because those are bad and so you know,
- 46:23Speaker 2: and those are part of There was an article that
- 46:25Speaker 2: came out last year that was like the fourteen modifiable
- 46:28Speaker 2: factors for Alzheimer's disease, and you know, three of them were.
- 46:32Speaker 3: Diabetes, obesity, and physical inactivity. Well to me, that's all Hey,
- 46:37Speaker 3: you know, this is all substrate utilization, right, you know,
- 46:40Speaker 3: And those are all inextricbly intertwined.
- 46:42Speaker 2: There.
- 46:43Speaker 3: Alcohol was in there as well, excess alcohol use, and
- 46:46Speaker 3: you know that's that's a that's a neurotoxin. And you know,
- 46:49Speaker 3: I would say that the right amount for just optimal physiology,
- 46:53Speaker 3: you know, is zero. And but anyway, that's that's another
- 46:57Speaker 3: conversation that's in my book too, and I have some
- 46:59Speaker 3: goodales for that, not just trying to ruin people's lives.
- 47:03Speaker 3: And then you know, elevated ApoB elevated LDLC in midlife
- 47:07Speaker 3: has been shown in several different studies as a risk
- 47:10Speaker 3: factor as well, although the lipid picture is complicated, right,
- 47:14Speaker 3: And that's why it's one of those things where one
- 47:17Speaker 3: of the things that people say a lot is, you know,
- 47:20Speaker 3: cumulative exposure to athroogenic clid proteins is like plaque ears,
- 47:25Speaker 3: you know, whereas packears are smoking, you know, you don't
- 47:27Speaker 3: just wait around to get lung cancer. You should stop today.
- 47:30Speaker 3: They say that that's the same sort of thing. As
- 47:33Speaker 3: far as you know LDL clusterol. If you have LDL
- 47:35Speaker 3: clustero al your whole life, well, you know, that's like
- 47:37Speaker 3: exposure exposure.
- 47:40Speaker 2: For a lot of people. I would say that that
- 47:42Speaker 2: tends to be true.
- 47:43Speaker 3: But I also don't think that that is fits quite
- 47:46Speaker 3: as well as my home security system in lipid neighborhood,
- 47:48Speaker 3: all right, because you have people, i mean with sky
- 47:51Speaker 3: high LDL clusterol levels their whole life and they get
- 47:55Speaker 3: zero disease.
- 47:58Speaker 2: Why what's protecting them? Right?
- 48:00Speaker 3: And so it's a little more complicated picture knowing that
- 48:02Speaker 3: LDL cholesterol itself is not, in my view, inherently toxic.
- 48:05Speaker 3: You know, all these ApoB life approteins, they're mail men, right, Well,
- 48:09Speaker 3: mail men go deliver the mail and then you know,
- 48:11Speaker 3: go home at the end of the day.
- 48:12Speaker 2: It's great.
- 48:13Speaker 3: Maybe you just live in a really busy, busy urban area,
- 48:16Speaker 3: you know, with a lot of mail men around, Okay,
- 48:20Speaker 3: And so I think that you know, now a lot
- 48:21Speaker 3: of people who have elevated lipids across their lifespan, yeah,
- 48:25Speaker 3: you know, they get broken into. And if you have really,
- 48:29Speaker 3: really really elevated lipids like homozygous F eight, you're going
- 48:32Speaker 3: to get broken into, regardless of your home security system.
- 48:34Speaker 1: Right.
- 48:35Speaker 3: But at the same time, there's a lot of things
- 48:37Speaker 3: we don't understand. I think we need to study the
- 48:39Speaker 3: people who have you know, an LDL clusterol two hundred
- 48:42Speaker 3: in their whole life and they have a cack of
- 48:44Speaker 3: zero and they live to be one hundred and eight.
- 48:46Speaker 2: Let's study those people.
- 48:47Speaker 3: Let's get their genome sequence and say, hey, why are
- 48:50Speaker 3: you so awesome? And then we can learn some more
- 48:53Speaker 3: things because lipids are really humbling. And you know, now,
- 48:57Speaker 3: like I said, the more you know, the more you know,
- 48:58Speaker 3: you don't know much.
- 49:00Speaker 1: Yeah, well, thank you for sharing with us today. And
- 49:03Speaker 1: I'm certain listeners are going to want to know where
- 49:05Speaker 1: to find you. Can they have a website LinkedIn, and
- 49:07Speaker 1: then where can they find your books?
- 49:09Speaker 2: Yeah?
- 49:10Speaker 3: So I do a lot of posting about various lipid
- 49:15Speaker 3: related topics on x formerly known as Twitter at Josh J. Wageman.
- 49:22Speaker 3: Is what it looks like w A G E M
- 49:24Speaker 3: A N. It's Wagman. But that confuses people. It's like
- 49:27Speaker 3: why is that either? That's a good question. So anyway,
- 49:29Speaker 3: so at Josh J. Wagman on if you on Amazon
- 49:33Speaker 3: dot com, if you just Google or not Google, just
- 49:37Speaker 3: search the home security system and the lipid neighborhood. My book,
- 49:41Speaker 3: which releases February eighteenth, will pop up. Unfortunately, pre order
- 49:45Speaker 3: is only available for the Kindle version for the ebook.
- 49:48Speaker 3: If you like that, that's great. But February eighteenth, if
- 49:52Speaker 3: you know, you go and you want to you know,
- 49:55Speaker 3: read some stuff about this, and you've found some of
- 49:57Speaker 3: the stuff in here interesting, then you know, you can
- 50:00Speaker 3: go on Februarer eighteenth and order it and then it'll
- 50:03Speaker 3: be at your house within a day or two.
- 50:05Speaker 2: And it's you know, my goal is not the goal
- 50:08Speaker 2: with this is.
- 50:08Speaker 3: Just to be a resource to just help people find
- 50:11Speaker 3: the signal, limits the noise when it comes to metabolism,
- 50:14Speaker 3: when it comes to cholesterol, understand how it's supposed to work,
- 50:17Speaker 3: Understand what can happen when it doesn't work right, and
- 50:20Speaker 3: understand what potentially to do about it. And so it's
- 50:23Speaker 3: you know, the e books like nine ninety nine, and
- 50:25Speaker 3: I anticipate the paperback will be like fourteen ninety nine.
- 50:29Speaker 3: So it's not going to you know, set you back
- 50:30Speaker 3: a whole bunch. And so that's my goal. I just
- 50:34Speaker 3: want people to read it, and I want to you know,
- 50:36Speaker 3: help us overall, whether you're a clinician, whether you're a
- 50:39Speaker 3: non clinician. I want to shift the paradigm from reactionary
- 50:42Speaker 3: to prevention.
- 50:43Speaker 2: And hope I help people add life to their years.
- 50:47Speaker 1: Yeah, exactly like you said. You want to stay cognitively
- 50:50Speaker 1: sharp and just be awesome.